利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.079 秒)

    Metformin Tablet with Sustained Release and Method for Preparing the Same
    1.
    发明申请
    Metformin Tablet with Sustained Release and Method for Preparing the Same 审中-公开
    具有持续释放的二甲双胍片剂及其制备方法

    公开(公告)号：US20070042042A1

    公开(公告)日：2007-02-22

    申请号：US11428619

    申请日：2006-07-05

    申请人： Young Jo ,  Ja-Seong Koo ,  Ju-Bin Yim ,  Yoon-Sik Jun

    发明人： Young Jo ,  Ja-Seong Koo ,  Ju-Bin Yim ,  Yoon-Sik Jun

    IPC分类号： A61K9/22 ,  A61K31/155

    CPC分类号： A61K9/0065 ,  A61K9/2054 ,  A61K9/2866 ,  A61K31/155

    摘要： The present invention relates to a metformin tablet with sustained release and a method for preparing the same, more particularly to an improved metformin tablet with sustained release prepared by manufacturing a composition comprising metformin, which is an active ingredient for treatment of insulin-independent diabetes, and a matrix capable of controlling release rate of metformin into a slug at a given pressure condition, forming a tablet core by dry granulation and then forming a coated film on it, which is slowly released into the body at a constant rate for 24 hours, thereby maintaining a constant blood concentration for 24 hours when administered once a day while offering bioequivalence comparable to that of conventional products, and a method for preparing the same.

    摘要翻译： 本发明涉及具有持续释放的二甲双胍片剂及其制备方法，更具体地涉及通过制备包含作为治疗胰岛素不依赖性糖尿病的活性成分的二甲双胍的组合物而制备的具有持续释放的改进的二甲双胍片剂， 以及能够在给定的压力条件下控制二甲双胍释放速率的基质，通过干法造粒形成片芯，然后在其上形成涂膜，以恒定速率缓慢释放24小时， 从而维持恒定的血液浓度24小时，每天一次给药，同时提供与常规产品相当的生物等效性及其制备方法。

    PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS OF METFORMIN EXTENDED RELEASE TABLETS
    2.
    发明申请
    PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS OF METFORMIN EXTENDED RELEASE TABLETS 审中-公开
    金属蛋白酶扩展片剂的药物组合物和配方

    公开(公告)号：US20070275061A1

    公开(公告)日：2007-11-29

    申请号：US11534359

    申请日：2006-09-22

    申请人： Young Gwan Jo ,  Ja-Seong Koo ,  Ju-Bin Yim ,  Yoon-Sik Jun

    发明人： Young Gwan Jo ,  Ja-Seong Koo ,  Ju-Bin Yim ,  Yoon-Sik Jun

    IPC分类号： A61K9/22 ,  A61K31/155

    CPC分类号： A61K31/155 ,  A61K9/2027 ,  A61K9/2054

    摘要： The present invention relates to a metformin extended release tablet, particularly to a metformin extended release tablet comprising metformin, which is effective in treating non-insulin dependent diabetes mellitus, as active ingredient, and a matrix in which hydrophilic polymers and hydrophobic materials are mixed at a specific proportion. The hydrophilic polymers enable controlling of the pore size of the gel layer formed by water swelling, thereby enabling primary control of drug release rate. And, the hydrophobic materials block the pores of the gel layer, thereby enabling secondary control of drug release rate. Therefore, the metformin extended release tablet of the present invention has better dissolution properties than conventional extended release tablets and, thus, enables extended drug release at constant rate even with less matrix. A constant blood level can be maintained with one administration a day and the tablet can be made smaller, which makes the administration easier and the production simpler.

    摘要翻译： 本发明涉及二甲双胍延长释放片剂，特别涉及二甲双胍延长释放片剂，其包含二甲双胍，其有效治疗作为活性成分的非胰岛素依赖性糖尿病，和将亲水性聚合物和疏水性材料混合在其中的基质 具体比例。 亲水性聚合物能够控制由水溶胀形成的凝胶层的孔径，从而能够初步控制药物释放速率。 并且，疏水材料阻挡凝胶层的孔，从而能够二次控制药物释放速率。 因此，本发明的二甲双胍延长释放片剂比常规延长释放片剂具有更好的溶解性能，因此即使使用较少的基质也能以恒定的速率延长药物释放。 可以每天一次给药维持恒定的血液水平，并且可以使片剂更小，这使得给药更容易并且生产更简单。

    COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY
    5.
    发明申请
    COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY 审中-公开
    基于循环理论治疗心血管疾病的联合制剂

    公开(公告)号：US20100047341A1

    公开(公告)日：2010-02-25

    申请号：US12445204

    申请日：2007-10-10

    申请人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja-Seong Koo ,  Sang Ouk Sun

    发明人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja-Seong Koo ,  Sang Ouk Sun

    IPC分类号： A61K9/54 ,  A61K9/24 ,  A61K31/4178

    CPC分类号： A61K31/4184 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/5084 ,  A61K31/4178 ,  A61K31/4422 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronotherapeutical combination pharmaceutical formulations with controlled-release for the prevention or treatment of cardiovascular disease, which is formulated in accordance with xenobiotics and chronotherapy for enabling the two drugs to be chronotherapeutically released, thereby improving the therapeutic activity as compared to the co-administration of each drug in the form of a single pill, while reducing side effects and maintaining the therapeutic activity as high as possible at the time of day when the risk of a complication of cardiovascular disease is highest.

    摘要翻译： 本发明涉及包含二氢吡啶类钙通道阻断剂如氨氯地平和ARB（血管紧张素-2受体阻断剂）如洛沙坦的功能性组合制剂。 特别地，本发明涉及具有控制释放以用于预防或治疗心血管疾病的时间疗法组合药物制剂，所述药物制剂根据异生素和时间疗法配制，以使两种药物能够进行治疗性释放，从而改善治疗活性 与单一药丸形式的每种药物的共同给药相比，同时在心血管疾病并发症的风险最高的一天中减少副作用并保持尽可能高的治疗活性。

    ANTI-CANCER PHARMACEUTICAL COMPOSITION
    6.
    发明申请
    ANTI-CANCER PHARMACEUTICAL COMPOSITION 审中-公开
    抗癌药物组合物

    公开(公告)号：US20140235559A1

    公开(公告)日：2014-08-21

    申请号：US14004746

    申请日：2011-06-15

    申请人： Sung-Wuk Kim ,  Sung-Soo Jun ,  Chang-Hee Min ,  Ja-Seong Koo ,  Jin-Wook Kim ,  Yong-Eun Kim ,  Sang-Ouk Sun

    发明人： Sung-Wuk Kim ,  Sung-Soo Jun ,  Chang-Hee Min ,  Ja-Seong Koo ,  Jin-Wook Kim ,  Yong-Eun Kim ,  Sang-Ouk Sun

    IPC分类号： A61K31/7004 ,  A61K9/48 ,  A61K9/28 ,  A61K31/155 ,  A61K31/506

    CPC分类号： A61K31/7004 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/155 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00

    摘要： Disclosed is an anticancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-glucose as active ingredients. These ingredients act in synergy with each other, thus exhibiting more potent inhibitory activity against the growth of cancer cells, compared to individual ingredients. Also, the synergistic anticancer activity allows the individual drugs to be used in lower amounts, which leads to a reduction in the occurrence of adverse effects. In addition, the time-lag release or administration of the ingredients decreases blood lactic acid levels to significantly mitigate the adverse effect of lactic acidosis, as well as exerting high anticancer effects. Particularly, the pharmaceutical composition can be formulated to dosage forms effective for therapy, increasing the drug compliance of the subject.

    摘要翻译： 公开了包含苯乙双胍或其药学上可接受的盐和2-脱氧-D-葡萄糖作为活性成分的抗癌药物组合物。 与各成分相比，这些成分彼此协同作用，因此对癌细胞的生长具有更强的抑制活性。 此外，协同抗癌活性允许以较低的量使用单独的药物，这导致副作用的发生减少。 此外，成分的时间延迟释放或给药降低了血液乳酸水平，以显着减轻乳酸性酸中毒的不利影响，并发挥高抗癌作用。 特别地，药物组合物可以配制成对治疗有效的剂型，增加受试者的药物依从性。